| Literature DB >> 25429565 |
Michał Antoszczak1, Ewa Maj2, Agnieszka Napiórkowska3, Joanna Stefańska4, Ewa Augustynowicz-Kopeć5, Joanna Wietrzyk6, Jan Janczak7, Bogumil Brzezinski8, Adam Huczyński9.
Abstract
A series of 12 novel monosubstituted N-benzyl amides of salinomycin (SAL) was synthesized for the first time and characterized by NMR and FT-IR spectroscopic methods. Molecular structures of three salinomycin derivatives in the solid state were determined using single crystal X-ray method. All compounds obtained were screened for their antiproliferative activity against various human cancer cell lines as well as against the most problematic bacteria strains such as methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE), and Mycobacterium tuberculosis. Novel salinomycin derivatives exhibited potent anticancer activity against drug-resistant cell lines. Additionally, two N-benzyl amides of salinomycin revealed interesting antibacterial activity. The most active were N-benzyl amides of SAL substituted at -ortho position and the least anticancer active derivatives were those substituted at the -para position.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25429565 PMCID: PMC6271077 DOI: 10.3390/molecules191219435
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Synthesis of monosubstitued N-benzyl amides of salinomycin.
The yields of the synthesis and the analytical signals in the 1H and 13C NMR spectra as well as the position of characteristic amide I and amide II bands in the FT-IR spectra of mono-substituted N-benzyl amides of SAL. 1H, 13C and 2D NMR spectra of selected Br- amide are included in the Supplementary material (Figures S1–S5).
| Compound | Yield (%) | Analytical NMR Signals (ppm) in CD2Cl2 | Characteristic FT-IR Bands (cm−1) | ||||
|---|---|---|---|---|---|---|---|
| 13C(1)=O | 1H-N(amide) | 13C(43) | 1H-C(43) | Amide I | Amide II | ||
| 84 | 175.7 | 6.92 | 40.7 | 4.75 (ddd, | 1660 | 1528 | |
| 72 | 175.8 | 6.89 | 42.5 | 4.80 (ddd, | 1658 | 1531 | |
| 79 | 175.7 | 6.97 | 42.3 | 4.74 (ddd, | 1651 | 1532 | |
| 73 | 175.3 | 6.90 | 41.3 | 4.82 (ddd, | 1660 | 1528 | |
| 80 | 175.8 | 7.15 | 42.4 | 4.81 (ddd, | 1648 | 1530 | |
| 77 | 175.7 | 7.03 | 42.4 | 4.75 (ddd, | 1658 | 1526 | |
| 71 | 175.8 | 6.98 | 44.0 | 4.73 (dq, | 1662 | 1528 | |
| 75 | 175.8 | 6.98 | 44.0 | 4.73 (dq, | 1658 | 1528 | |
| 67 | 175.8 | 7.03 | 42.4 | 4.73 (ddd, | 1658 | 1525 | |
| 81 | 176.1 | 7.18 | 41.3 | 5.00 (dq, | 1665 | 1530 | |
| 69 | 176.2 | 7.37 | 42.4 | 4.94 (ddd, | 1657 | 1532 | |
| 76 | 176.2 | 7.30 | 42.7 | 4.93 (ddd, | 1660 | 1523 | |
Figure 2FT-IR spectra of salinomycin sodium salt (SAL-Na), salinomycin (SAL) and p-chlorobenzyl amide of salinomycin (Cl-) made for KBr tablet; (a) 4000–400 cm−1; (b) 3700–2750 cm−1; (c) 1800–1350 cm−1.
Figure 3View of the molecular structures of SAL amides: (a) F-, (b) F- and (c) NO.
Hydrogen-bond geometry (Å, °) in the crystal structures of SAL benzyl amides (F-, F- and NO).
| D-H···A | D-H | H···A | D···A | D-H···A |
|---|---|---|---|---|
| 0.82 (2) | 2.27 (2) | 3.016 (2) | 152 (2) | |
| 0.82 (2) | 2.31 (2) | 2.728 (2) | 113 (1) | |
| 0.82 (2) | 2.26 (2) | 3.075 (2) | 172 (2) | |
| 0.82 (2) | 2.27 (2) | 3.017 (2) | 152 (1) | |
| 0.86 (2) | 2.46 (2) | 3.166 (2) | 139 (2) | |
| 0.82 (2) | 2.28 (2) | 3.013 (2) | 150 (2) | |
| 0.82 (2) | 2.40 (2) | 2.700 (2) | 103 (1) | |
| 0.82 (2) | 2.36 (2) | 3.147 (2) | 161 (1) | |
| 0.82 (2) | 2.17 (2) | 2.980 (2) | 172 (2) | |
| 0.86 (2) | 2.25 (2) | 3.048 (2) | 155 (2) | |
| 0.82 (2) | 2.45 (2) | 3.066 (2) | 133 (1) | |
| 0.82 (2) | 2.26 (2) | 2.728 (2) | 117 (1) | |
| 0.82 (2) | 2.13 (2) | 2.873 (2) | 151 (1) | |
| 0.82 (2) | 2.10 (2) | 2.789 (2) | 141 (1) | |
| 0.86 (2) | 2.27 (2) | 3.013 (2) | 145 (1) | |
Symmetry code: (i) x+1, y, z; (j) x, y+1, z; (k) x−1, y, z.
Figure 4ESI spectra of a mixture of Cl- with MClO4 (M = Li, Na, K, Rb, Cs) at cv = 30 V.
Figure 5ESI spectra of a mixture of Cl- with M(ClO4)2 (M = Mg, Ca, Sr, Ba) at cv = 30 V.
Anticancer activity of SAL and its monosubstituted N-benzyl amides. Data are given as IC50 [µM].
| Compound | Cancer Cells | Normal Cells | ||||
|---|---|---|---|---|---|---|
| HL-60 | HL-60/vinc | LoVo | LoVo/dx | BALB/3T3 | ||
| 0.33 ± 0.12 | 2.33 ± 0.12 | 0.47 ± 0.08 | 0.81 ± 0.32 | 13.02 ± 7.90 | ||
| 3.63 ± 0.14 | 4.44 ± 1.73 | 3.49 ± 0.59 | 2.32 ± 0.69 | 5.97 ± 2.07 | ||
| 64.95 ± 35.32 | NA | 13.53 ± 0.28 | 3.91 ± 2.10 | 6.46 ± 1.11 | ||
| 3.60 ± 0.69 | 11.79 ± 2.56 | 6.18 ± 0.91 | 3.29 ± 0.91 | 8.63 ± 1.96 | ||
| 3.18 ± 0.69 | 3.99 ± 1.47 | 3.85 ± 0.05 | 2.91 ± 0.22 | 6.00 ± 2.26 | ||
| 3.83 ± 0.09 | 6.59 ± 1.22 | 11.62 ± 5.12 | 2.96 ± 0.99 | 17.34 ± 8.94 | ||
| 36.19 ± 3.03 | 46.81 ± 12.45 | 19.27 ± 4.03 | 16.58 ± 4.81 | 7.62 ± 1.44 | ||
| 3.13 ± 0.71 | 4.80 ± 1.48 | 3.64 ± 0.07 | 2.87 ± 0.29 | 6.51 ± 3.23 | ||
| 3.38 ± 1.09 | 7.08 ± 1.73 | 5.23 ± 0.22 | 3.39 ± 0.15 | 9.25 ± 1.84 | ||
| 20.66 ± 4.66 | 33.52 ± 10.88 | 16.29 ± 0.96 | 4.97 ± 2.76 | 8.39 ± 2.70 | ||
| 3.47 ± 0.44 | 6.84 ± 2.04 | 3.81 ± 0.18 | 2.45 ± 0.26 | 9.55 ± 2.81 | ||
| 8.78 ± 1.73 | 24.57 ± 8.00 | 16.15 ± 1.61 | 3.26 ± 0.84 | 24.91 ± 2.42 | ||
| NA | NA | 13.30 ± 1.94 | 20.40 ± 8.63 | 6.91 ± 1.86 | ||
| 0.04 ± 0.04 | 0.88 ± 0.26 | 0.15 ± 0.06 | 5.46 ± 1.56 | 0.18 ± 0.07 | ||
| 1.00 ± 0.23 | 6.87 ± 1.63 | 3.70 ± 1.20 | 5.20 ± 1.93 | 5.30 ± 2.93 | ||
The IC50 value is defined as the concentration of a compound that corresponds to a 50% growth inhibition. Human promyelocytic leukemia (HL-60) and its vincristine-resistant subline (HL-60/vinc); human colon adenocarcinoma cell line (LoVo) and doxorubicin resistant subline (LoVo/dx); normal murine embryonic fibroblast cell line (BALB/3T3). Data are expressed as the mean ± SD; NA: not active in concentrations used (up to 100 µg/mL).
The calculated values of the indexes of resistance (IR) and selectivity (SI) of SAL and its N-benzyl amides.
| Compound | HL-60 | HL-60/vinc | LoVo | LoVo/DX | ||
|---|---|---|---|---|---|---|
| SI | SI | IR | SI | SI | IR | |
| 39.45 | 5.59 | 7.06 | 27.70 | 16.07 | 1.72 | |
| 1.64 | 1.34 | 1.22 | 1.71 | 2.57 | 0.66 | |
| 0.10 | - | - | 0.48 | 1.65 | 0.29 | |
| 2.40 | 0.73 | 3.28 | 1.40 | 2.62 | 0.53 | |
| 1.89 | 1.50 | 1.25 | 1.56 | 2.06 | 0.76 | |
| 4.52 | 2.63 | 1.72 | 1.49 | 5.86 | 0.25 | |
| 0.21 | 0.16 | 1.29 | 0.40 | 0.46 | 0.86 | |
| 2.08 | 1.36 | 1.53 | 1.79 | 2.27 | 0.79 | |
| 2.74 | 1.31 | 2.09 | 1.77 | 2.73 | 0.65 | |
| 0.41 | 0.25 | 1.62 | 0.52 | 1.69 | 0.30 | |
| 2.75 | 1.40 | 1.97 | 2.51 | 3.90 | 0.64 | |
| 2.84 | 1.01 | 2.80 | 1.54 | 7.64 | 0.20 | |
| - | - | - | 0.52 | 0.34 | 1.53 | |
| 4.50 | 0.20 | 22.00 | 1.20 | 0.03 | 36.40 | |
| 5.30 | 0.77 | 6.87 | 1.43 | 1.02 | 1.41 | |
The IR and SI values were calculated for each compounds using formula: RI = IC50 for drug-resistant cell line/IC50 for appropriate drug-sensitive cell line; SI = IC50 for normal cell line (BALB/3T3)/IC50 for respective cancerous cell line.
Antibacterial activity of SAL as well as its F- and NO amides and ciprofloxacin, designated as diameter of GIZ (mm) and MIC (µg/mL).
| Bacterial Strains | SAL | F- | NO2- | ciprofloxacin | ||||
|---|---|---|---|---|---|---|---|---|
| GIZ | MIC | GIZ | MIC | GIZ | MIC | GIZ | MIC | |
| 30 | 2 | 18 | 32 | un | 128 | 26 | 0.25 | |
| 29 | 2 | 19 | 32 | un | 128 | 26 | 0.5 | |
| 34 | 2 | 19 | 16 | un | 128 | 28 | 0.25 | |
| 28 | 4 | 20 | 32 | un | 128 | 22 | 0.5 | |
| 34 | 2 | 20 | 16 | un | 128 | 30 | 0.25 | |
| 33 | 2 | 18 | 32 | un | 128 | 32 | 0.125 | |
un: unmeasurable.
Antibacterial activity of SAL as well as its F- and NO amides against MRSA and MRSE designated as MIC (µg/mL).
| SAL | F- | NO2- | Ciprofloxacin | |
|---|---|---|---|---|
| MIC | MIC | MIC | MIC | |
| 452/11 | 16 | 16 | 128 | 32 |
| 456/11 | 16 | 16 | 128 | 32 |
| 462/11 | 16 | 32 | 128 | 64 |
| 514/11 | 8 | 32 | 128 | 32 |
| 522/12 | 16 | 32 | 128 | 32 |
| 537/12 | 16 | 32 | 256 | 64 |
| 572/12 | 16 | 32 | 128 | 64 |
| 573/12 | 16 | 64 | 256 | 32 |
| 585/12 | 16 | 32 | 256 | 64 |
| 586/12 | 16 | 64 | 256 | 64 |
| 459/11 | 16 | 32 | 128 | 16 |
| 460/11 | 16 | 32 | 128 | 0.125 |
| 461/11 | 16 | 32 | 256 | 0.25 |
| 466/11 | 8 | 16 | 256 | 2 |
| 467/11 | 16 | 64 | 128 | 16 |
| 468/11 | 16 | 64 | 128 | 16 |
| 469/11 | 16 | 64 | 256 | 8 |
| 470/11 | 16 | 32 | 256 | 0.125 |
| 488/11 | 16 | 128 | 256 | 16 |
| 489/11 | 16 | 32 | 256 | 0.25 |
Antitubercular activity of SAL and its N-benzyl amides. Data are given as MIC [µg/mL].
| Compound | |||
|---|---|---|---|
| Standard H37Rv Strain | Isoniazid-Sensitive Strain | Isoniazid-Resistant Strain | |
| 25 | 25 | 50 | |
| 100 | 50 | 100 | |
| 100 | >100 | >100 | |
| 50 | 50 | 50 | |
| 100 | 50 | >100 | |
| 100 | >100 | >100 | |
| 100 | 100 | >100 | |
| >100 | >100 | >100 | |
| >100 | >100 | >100 | |
| 50 | 50 | 100 | |
| 50 | 50 | 100 | |
| 100 | 100 | >100 | |
| 50 | 50 | 50 | |
| <3.1 | <3.1 | 6.25 | |